Výsledky vyhledávání - "Jose Maria Garcia-Bueno"

Predictors for survival with cabazitaxel (CBZ) in metastatic, castration-resistant prostate cancer (mCRPC): Long term follow-up of the Spanish registry

Publikováno v: Journal of Clinical Oncology. 35:e602-e602

e602 Background: The clinical experience with CBZ in mCRPC patients (pts) has enriched notably since its approval for clinical use, but there is still a lack of well-defined prognostic/predictive factors to better characterize the profile of pts that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e37420e76066302e3c5bb4f809d7a9e
https://doi.org/10.1200/jco.2017.35.6_suppl.e602

Zobrazit plný text záznamu

Risk model for clinically relevant neutropenic event among patients with non hematological tumors receiving chemotherapy regimens not classified as high-risk for febrile neutropenia: results from a multicenter prospective cohort study (NEURISK)

Autor: J. Muñoz-Langa, P. Purificación Martínez del Prado, J.M. Campos, Miguel Lázaro, V. Valentí Moreno, E. Jiménez Orozco, Jose Maria Garcia-Bueno, R. Lopez Castro, M. Quindos, P. Borrega

Publikováno v: Annals of Oncology. 27:vi503

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d7c45bdfc1e5f9133c3e3ba2a8576d6
https://doi.org/10.1093/annonc/mdw390.20

Zobrazit plný text záznamu

Geinofote: Safety and Activity Analysis of the Use of Fotemustine (Ft) in Different Schedules in Progressive Glioblastoma (Gb) in Spain

Publikováno v: Annals of Oncology. 25:iv142

Aim: Previous studies showed that FT may be useful as treatment in recurrent GB. The present study evaluate the activity and toxicity of FT in recurrent malignant GB patients in the clinical setting in Spain. Methods: Patients (age >18 years) with GB

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72d3b165967010f895e54573b52b94d2
https://doi.org/10.1093/annonc/mdu330.17

Zobrazit plný text záznamu

GEINOFOTE: Safety and activity analysis of the use of fotemustine (FT) in different schedules in progressive high-grade glioma (HGG) in Spain

Publikováno v: Journal of Clinical Oncology. 32:2055-2055

2055 Background: Previous studies showed that FT may be useful as treatment in recurrent high-grade glioma (HGG). The present study evaluate the activity and toxicity of FT in recurrent malignant g...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66c7be0acb287a5959c818d2aabe54d5
https://doi.org/10.1200/jco.2014.32.15_suppl.2055

Zobrazit plný text záznamu

Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results

Publikováno v: Journal of Clinical Oncology. 32:e16088-e16088

e16088 Background: New emerging therapies for mCRPC, such as CBZ, have prompted the need to identify appropriate patients (pts) for each specific treatment. Updated data on the experience with CBZ ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea075a647c4940fbe5faef00181dddaf
https://doi.org/10.1200/jco.2014.32.15_suppl.e16088

Zobrazit plný text záznamu

Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience

Autor: Begoña Perez-Valderrama, Emilio Esteban, Jose Maria Garcia-Bueno, Daniel Castellano, Gustavo Rubio, Almudena Martin, Ana Reyes Garcia, Joaquim Bellmunt, Javier Munarriz, Quionia Pérez Arnillas, Jose Garcia Sanchez, M. Laura Villalobos Leon, Jose David Cumplido Buron, Urbano Anido Herranz, Begoña Campos Balea, Iria Gonzalez Maeso

Publikováno v: Journal of Clinical Oncology. 32:235-235

235 Background: New emerging therapies for metastatic castration resistant prostate cancer (mCRPC), such as cabazitaxel (CBZ), have prompted the need to identify appropriate patients (pts) for each specific treatment. We describe preliminary data on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b168870578e3660748eb748bf7e4bc5
https://doi.org/10.1200/jco.2014.32.4_suppl.235

Zobrazit plný text záznamu

Clinical Profile and Patterns of Progression (PD) of Patients (PTS) with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC) Treated with First Line Bevacizumab (B): Avva Study

Autor: Oscar Juan, Ramon Garcia-Gomez, Belen Saenz Rubio, María Sereno, Manuel Domine, S. Saura, J. de Castro, M. Cobo, Jose Maria Garcia-Bueno, E. Pujol

Publikováno v: Annals of Oncology. 23:ix441

Background B in combination with platinum doublets prolongs survival and delays PD in chemo-naive pts with advanced nsNSCLC and its safety profile has been widely described in clinical trials. In this study we aim to evaluate the behavior, clinical p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::542e787c24679bfb0eb95b161eebd2a9
https://doi.org/10.1016/s0923-7534(20)33815-1

Zobrazit plný text záznamu

Clinical profile and patterns of progression (PD) of patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line bevacizumab (B): AVVA study

Autor: Javier de Castro, Belen Rubio, Ramon Garcia-Gomez, Salvador Saura, María Sereno, E. Pujol, Jose Maria Garcia-Bueno, Manuel Domine, Manuel Cobo, Oscar Juan

Publikováno v: Journal of Clinical Oncology. 30:e18015-e18015

e18015 Background: B in combination with platinum doublets prolongs survival and delays PD in chemo-naïve pts with advanced nsNSCLC and its safety profile has been widely described in clinical trials. In this study we aim to evaluate the behavior, c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f6b4359e9479665f8e38b34eaefa3b9
https://doi.org/10.1200/jco.2012.30.15_suppl.e18015

Zobrazit plný text záznamu

Clinical outcomes for special populations of patients treated with first-line bevacizumab-based therapy in an observational study (AVVA)

Autor: Jose Maria Garcia-Bueno, E. Pujol, O. Juan Vidal, Manuel Domine, J. de Castro, B. Rubio-Viqueira, Regina Garcia, S. Saura, María Sereno, M. Cobo

Publikováno v: Journal of Clinical Oncology. 29:e18033-e18033

e18033 Background: More than 50% of cases of advanced NSCLC are diagnosed in patients (pts) older than 65 years. Furthermore, the majority of pts with NSCLC present at the time of the diagnosis one...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6788d680354d00c52eca4b9b258b55a8
https://doi.org/10.1200/jco.2011.29.15_suppl.e18033

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání